

## EDUCATION, SCIENCE AND TRAINING

### SENATE LEGISLATION COMMITTEE – QUESTIONS ON NOTICE 2003-2004 SUPPLEMENTARY ESTIMATES HEARING

**Outcome:** CSIRO  
**Output Group:** - CSIRO

#### **DEST Question No. E605\_04**

Senator Carr asked on 5 November 2003.

#### **Question:**

Note 26 (page 139) refers to the Biomolecular Research Institute Ltd.

What products are under development by BMI?

#### **Answer:**

CSIRO has provided the following response.

*Joint Ventures – Biomolecular Research Institute (BRI)*

[Please note that for the following questions in relation to note 26 (page 139), we have taken reference to BMI as meaning BRI.]

BRI Ltd was established to create a high level Australian research facility with critical mass in the field of structural biology, particularly as applied in the medical/pharmaceutical field. As a research facility the BRI has not sought to develop products itself, but instead has out-licensed its intellectual property for product development and exploitation.

The major intellectual property developed by the BRI is novel dendrimer technology, part of which was licensed by BRI to Starpharma (Pooled Development Ltd), an independent spin-off company formed to exploit this technology. Starpharma is developing the dendrimer technology for use in anti-viral, anti-microbial and anti-parasite therapeutic products.